Chronic neutrophilic leukemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 9: Line 9:
CNL must be differentiated from other diseases that cause [[neutrophilia]].
CNL must be differentiated from other diseases that cause [[neutrophilia]].


===Differentiating CNL from other diseases on the basis of neutrophilia:===
==Differentiating Leukemia from other Diseases==
* '''Leukemoid reaction:''' leukemoid reaction is responsible for the most of neutrophilia. Notable neutrophilia, bone marrow hypercellularity, normal cytogenetics, and absence of BCR-ABL gene are seen in both leukemoid reaction and neutrophilia. WBC count may be more modestly elevated in leukemoid reaction, though there have been some reports of WBC counts up to 100 × 109/L in this context34. Meticulous history-taking along with a thorough clinical examination to exclude alternate diagnoses, including occult malignancy or infection, and a period of observation is often recommended before formally determining the diagnosis. The demonstration of clonality including identification of  a CSF3R mutation or other molecular or cytogenetic abnormality is clearly valuable in aligning the diagnosis in favor of CNL. CML is invariably associated with a BCR-ABL fusion gene and displays a disproportionally higher percentage of myelocytes. CML also commonly presents with basophilia, thrombocytosis, or eosinophilia. While the absence of the Philadelphia chromosome is implicit to CNL diagnosis, a rare form of CML termed neutrophilic-CML, or CML-N, has been described which shares morphological features of CNL, specifically a prominent neutrophilic proliferation35. CML-N, however, is characterized by an uncommon BCR-ABL translocation which results in the transcription of an e19/a2 type BCR-ABL messenger RNA yielding a 230-kD BCR-ABL protein (p230)12,36. The clinical correlate is a lower total WBC count, less severe anemia, less prominent splenomegaly, and blastic transformation occurring much later in CML-N patients35. The attenuated phenotype and indolent course of CMLN, specifically in patients without additional cytogenetic abnormalities, is now postulated to be due to low p230 mRNA and protein levels37. The diagnosis of CNL also requires that molecular testing be negative for defining markers of alternate neoplasms including not only the BCR-ABL1 fusion gene but also rearrangements in PDGFRA/B or FGFR1, characteristic of eosinophilic leukemia.
Leukemia must be differentiated from various diseases that cause [[weight loss]], [[night sweats]], [[hepatosplenomegaly]], and palpable [[lymph node]]s, such as [[hairy cell leukaemia|hairy cell leukemia]], prolymphocytic leukemia, [[follicular lymphoma]], and [[mantle cell lymphoma]]. Based on the expression of cell surface markers, the table below differentiates different types of leukemia from other diseases that cause similar clinical presentations:<ref name="H">Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011</ref>
*Leukemoid reaction is the most common cause of neutrophilia. A detailed clinical history is useful to rule out underlying chronic infection or malignancy. The neutrophilia associated with malignancies could result from several factors, such as bone marrow metastasis, inflammatory reaction to necrosis, or production of cytokines by the tumour or in response to it.33 The white cell count is modestly elevated; however, rare cases with white cell count up to 100×109/L have been reported.34 Several cytokines are reported to play role including granulocyte-monocyte CSF (GM-CSF), interleukin-1 (IL-1), G-CSF and interleukin-6 (IL-6). The possibility of underlying occult malignancy should be excluded in all cases of sustained and unexplained neutrophilia. A careful clinical history, a thorough clinical evaluation and a period of observation are usually helpful to rule out these reactive causes. Detection of CSF3R mutation can be of great value in cases with unexplained persistent neutrophilia.
* '''CML'''
* '''CML-N'''
* '''MPN/MDS disorders:''' such as aCML (atypical chronic myeloid leukemia) and CMML (chronic myelomonocytic leukemia)
* '''Polycythemia vera'''
* '''Essential thrombocythemia'''
* '''Primary myelofibrosis'''


{|
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! colspan="11" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Manifestation
! colspan="3" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
|-
! align="center" style="background:#DCDCDC;" + |[[Acute myelogenous leukemia]]<ref name="pmid30410824">{{cite journal |vauthors=Saif A, Kazmi SFA, Naseem R, Shah H, Butt MO |title=Acute Myeloid Leukemia: Is That All There Is? |journal=Cureus |volume=10 |issue=8 |pages=e3198 |date=August 2018 |pmid=30410824 |doi=10.7759/cureus.3198 |url=}}</ref><ref name="pmid23526416">{{cite journal |vauthors=Estey EH |title=Acute myeloid leukemia: 2013 update on risk-stratification and management |journal=Am. J. Hematol. |volume=88 |issue=4 |pages=318–27 |date=April 2013 |pmid=23526416 |doi=10.1002/ajh.23404 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Clonal proliferation of malignant myeloid blast cells in the marrow
* Genetic abnormalities t(8;21), inv(16), and t(15;17)
| align="left" style="background:#F5F5F5;" + |
* The most common type of acute leukemia in adults
* Median age of 63 years old
* More in [[congenital]] disorders such as  [[Down syndrome]], [[Bloom syndrome]]
| align="left" style="background:#F5F5F5;" + |
* [[Smoking]], previous [[chemotherapy]] or [[radiation therapy]], [[myelodysplastic syndrome]], and exposure to the chemical [[benzene]]
| align="left" style="background:#F5F5F5;" + |
* [[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | –
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |Mild and asymptomatic
| align="left" style="background:#F5F5F5;" + |
* Bone [[tenderness]]
* [[Dyspnea]]
* Leukemia cutis
* Swelling of the [[Gingiva|gums]]
* Chloroma
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[Thrombocytopenia]]
* [[Leukocytosis]] or [[leukopenia]]
| align="left" style="background:#F5F5F5;" + |
* Leukemic blasts
* Positive [[Auer rod|Auer rods]]
| align="center" style="background:#F5F5F5;" + |NA
| align="left" style="background:#F5F5F5;" + |
* [[Flow cytometry]] > 20% blasts of [[myeloid]] lineage
| align="left" style="background:#F5F5F5;" + |
* Persistent or frequent [[infections]]
* Fatal within weeks or months if left untreated
|-
! align="center" style="background:#DCDCDC;" + |[[Acute lymphoblastic leukemia]]<ref name="pmid30302234">{{cite journal |vauthors=Sawalha Y, Advani AS |title=Management of older adults with acute lymphoblastic leukemia: challenges & current approaches |journal=Int J Hematol Oncol |volume=7 |issue=1 |pages=IJH02 |date=March 2018 |pmid=30302234 |pmc=6176956 |doi=10.2217/ijh-2017-0023 |url=}}</ref><ref name="pmid23841506">{{cite journal |vauthors=Portell CA, Advani AS |title=Novel targeted therapies in acute lymphoblastic leukemia |journal=Leuk. Lymphoma |volume=55 |issue=4 |pages=737–48 |date=April 2014 |pmid=23841506 |doi=10.3109/10428194.2013.823493 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Arrest of  [[lymphoblasts]]
* Chromosomal translocations: t(9;22) , t(12;21), t(5;14), t(1;19)
| align="left" style="background:#F5F5F5;" + |
* The most common form of cancer in children
*Peak 2-5 years of age
*Boys > girls
| align="left" style="background:#F5F5F5;" + |
* History of [[cancer]]
* History of drug exposure
| align="left" style="background:#F5F5F5;" + |
* Generalized weakness and [[Fatigue (physical)|fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | –
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* Musculoskeletal pain
* [[Dyspnea]]
* [[Pallor]]
* [[Papilledema]]
* [[Meningism|Nuchal rigidity]]
* [[Cranial nerve palsy]]
* [[Testicle|Testicular]] enlargement
* [[Mediastinal mass]]
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[Thrombocytopenia]] 
* Normal or slightly increased [[White blood cells|WBC]] counts 
| align="left" style="background:#F5F5F5;" + |
* [[Lymphoblast|Lymphoblasts]]
* Atypical cells
| align="center" style="background:#F5F5F5;" + |NA
| align="left" style="background:#F5F5F5;" + |
* [[Bone marrow examination|Bone marrow biopsy]]
| align="left" style="background:#F5F5F5;" + |
* [[CNS]] involvement
|-
! align="center" style="background:#DCDCDC;" + |[[Chronic myelogenous leukemia]]<ref name="pmid25814082">{{cite journal |vauthors=Saußele S, Silver RT |title=Management of chronic myeloid leukemia in blast crisis |journal=Ann. Hematol. |volume=94 Suppl 2 |issue= |pages=S159–65 |date=April 2015 |pmid=25814082 |doi=10.1007/s00277-015-2324-0 |url=}}</ref><ref name="pmid30285354">{{cite journal |vauthors=Eden RE, Coviello JM |title= |journal= |volume= |issue= |pages= |date= |pmid=30285354 |doi= |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Dysregulated production and uncontrolled proliferation of mature and maturing [[Granulocyte|granulocytes]]
* [[BCR/ABL|BCR-ABL1]] fusion gene
* [[Dominance relationship|Autosomal dominant]] mutation
| align="left" style="background:#F5F5F5;" + |
* Median age 50 years old
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
* Generalized [[Muscle weakness|weakness]] and [[Fatigue (physical)|fatigue]]
* [[Satiety|Early satiety]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Abdominal fullness
| align="left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
*Asymptomatic
*[[Blast crisis]] resembling acute leukemia
*Excessive [[Perspiration|sweating]]
* [[Papilledema]]
* [[Tenderness]] over the lower [[sternum]]
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[White blood cells|WBC]] > 100,000/microL
* Absolute [[basophilia]] and [[eosinophilia]]
* [[Platelet|Plt]] > 600,000 to 700,000/microL
| align="left" style="background:#F5F5F5;" + |
* All cells of the neutrophilic series, from [[Myeloblast|myeloblasts]] to mature [[Neutrophil|neutrophils]]
* [[Myelocyte]] bulge
| align="left" style="background:#F5F5F5;" + |
* Low [[leukocyte alkaline phosphatase]]
* High [[uric acid]]
| align="left" style="background:#F5F5F5;" + |
* [[Bone marrow examination|Bone marrow biopsy]]
| align="left" style="background:#F5F5F5;" + |
* Acute [[Gout|gouty arthritis]]
* Venous obstruction
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
! align="center" style="background:#DCDCDC;" + |'''Chronic lymphocytic leukemia'''<ref name="pmid266906142">{{cite journal |vauthors=Rai KR, Jain P |title=Chronic lymphocytic leukemia (CLL)-Then and now |journal=Am. J. Hematol. |volume=91 |issue=3 |pages=330–40 |date=March 2016 |pmid=26690614 |doi=10.1002/ajh.24282 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Progressive accumulation of monoclonal [[B cell|B lymphocytes]]
| align="left" style="background:#F5F5F5;" + |
* The most common leukemia in adults in western countries
* M > F
* Median age 70 years old
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Exposure to [[Herbicide|herbicides]] or [[Insecticide|insecticides]]
| align="left" style="background:#F5F5F5;" + |
* Generalized [[weakness]]
* [[Anorexia]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
The most common abnormal finding
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* [[Skin lesion|Skin lesions]] (leukemia cutis)
* [[Sleep hyperhidrosis|Night sweats]]
* [[Muscle wasting]]
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[Thrombocytopenia]]
* Absolute [[lymphocytosis]] >5000 cells/μl
* [[Neutropenia]]
| align="left" style="background:#F5F5F5;" + |
* Presence of smudge cells
* Monoclonality of [[Light chain|kappa]] and [[Lambda (anatomy)|lambda]] producing [[B cell|B cells]]
* Express [[CD19]], [[CD20]], [[CD23]], and [[CD5]] on the [[cell]] surface
| align="left" style="background:#F5F5F5;" + |
* Positive direct antiglobulin (Coombs) test
* [[Hypogammaglobulinemia]]
* Elevated levels of serum [[lactate dehydrogenase]] and [[beta-2 microglobulin]]
| align="left" style="background:#F5F5F5;" + |
* [[Flow cytometry]] of the [[Venous blood|peripheral blood]]
| align="left" style="background:#F5F5F5;" + |
* Extranodal involvement of [[skin]], [[kidney]], [[lung]], [[Spinal cord|spine]]
* [[Membranoproliferative glomerulonephritis]]
* [[Autoimmune hemolytic anemia]]
|-
! align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]<ref name="pmid29110361">{{cite journal |vauthors=Troussard X, Cornet E |title=Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment |journal=Am. J. Hematol. |volume=92 |issue=12 |pages=1382–1390 |date=December 2017 |pmid=29110361 |pmc=5698705 |doi=10.1002/ajh.24936 |url=}}</ref><ref name="pmid29118233">{{cite journal |vauthors=Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H |title=Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology |journal=J Natl Compr Canc Netw |volume=15 |issue=11 |pages=1414–1427 |date=November 2017 |pmid=29118233 |doi=10.6004/jnccn.2017.0165 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Accumulation of small mature [[B cell]] lymphoid cells with abundant [[cytoplasm]] and "hairy" projections
* [[BRAF]] mutation
| align="left" style="background:#F5F5F5;" + |
* Uncommon
* Median age 50 to 55 years old
* M >> F
* More common in Caucasians than Blacks
| align="left" style="background:#F5F5F5;" + |
* Exposures to [[ionizing radiation]], [[Pesticide|pesticides]], and farming
| align="left" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]] and [[fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Abdominal fullness
| align="left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + | +
[[Splenomegaly]]
| align="left" style="background:#F5F5F5;" + |
* Asymptomatic
* Spontaneous [[splenic rupture]]
* [[Rash|Skin rash]]
* [[Ascites]]
* [[Pleural effusion]]
| align="left" style="background:#F5F5F5;" + |
* [[Cytopenia]]
* [[Leukocytosis]] in 10 to 20 percent
| align="left" style="background:#F5F5F5;" + |
* [[Pancytopenia]] with [[monocytopenia]] and circulating tumor cells characteristic of HCL
* Dry [[bone marrow]]
| align="left" style="background:#F5F5F5;" + |
* [[Azotemia]]
* Abnormal [[liver function tests]]
* [[Hypergammaglobulinemia]]
| align="left" style="background:#F5F5F5;" + |
* Analysis of [[Venous blood|peripheral blood]] + [[immunophenotyping]] by [[flow cytometry]]
| align="left" style="background:#F5F5F5;" + |
* [[Vasculitis]]
|-
! align="center" style="background:#DCDCDC;" + |Large granular lymphocytic leukemia<ref name="pmid28128670">{{cite journal |vauthors=Matutes E |title=Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options |journal=Expert Rev Hematol |volume=10 |issue=3 |pages=251–258 |date=March 2017 |pmid=28128670 |doi=10.1080/17474086.2017.1284585 |url=}}</ref><ref name="pmid28717070">{{cite journal |vauthors=Oshimi K |title=Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias |journal=Intern. Med. |volume=56 |issue=14 |pages=1759–1769 |date=2017 |pmid=28717070 |pmc=5548667 |doi=10.2169/internalmedicine.56.8881 |url=}}</ref>​
| align="center" style="background:#F5F5F5;" + |
* Clonal proliferation of cytotoxic T cells
* Dysregulation of apoptosis through abnormalities in the Fas/Fas ligand pathway
| align="center" style="background:#F5F5F5;" + |
* Rare
* Median age 60 years
* M = F
| align="center" style="background:#F5F5F5;" + |
* Autoimmune diseases
* Lymphoproliferative disorders
| align="center" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]] and [[fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* Mostly asymptomatic
| align="center" style="background:#F5F5F5;" + |
* Modest lymphocytosis
* Neutropenia
* Anemia
* Thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
* Large lymphocytes with a condensed round or oval nucleus, abundant pale basophilic cytoplasm, and small azurophilic granules
| align="center" style="background:#F5F5F5;" + |
* Multiple serological abnormalities including rheumatoid factor, antinuclear antibody, antiplatelet antibodies, antineutrophil antibodies, positive direct Coombs test, hyper- or hypogammaglobulinemia, monoclonal gammopathies, and elevated β2-microglobulin
| align="center" style="background:#F5F5F5;" + |
* Biopsy and flow cytometry + T-cell receptor gene rearrangement studies
| align="center" style="background:#F5F5F5;" + |
* Recurrent bacterial infection
|-
! align="center" style="background:#DCDCDC;" + |[[Chronic neutrophilic leukemia]]<ref name="pmid29512199">{{cite journal |vauthors=Elliott MA, Tefferi A |title=Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management |journal=Am. J. Hematol. |volume=93 |issue=4 |pages=578–587 |date=August 2018 |pmid=29512199 |doi=10.1002/ajh.24983 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Mature granulocytic proliferation in the blood and marrow
* Point mutations in the CSF3R gene
| align="center" style="background:#F5F5F5;" + |
* Very rare
* M = F
| align="center" style="background:#F5F5F5;" + |
* Multiple myeloma
| align="center" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]] and [[fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + | +
The most common clinical finding
| align="center" style="background:#F5F5F5;" + |
* Pruritus
* Gout
| align="center" style="background:#F5F5F5;" + |
* Peripheral blood neutrophilia (> 25 x 10<sup>9</sup>/L) with myeloid precursors (promyelocytes, myelocytes, metamyelocytes)
| align="center" style="background:#F5F5F5;" + |
* Toxic granulation in the [[Neutrophil|neutrophils]]
* Nuclear hypersegmentation
* Increased myeloid:erythroid ratio > 20:1
| align="center" style="background:#F5F5F5;" + |
* Elevated [[leukocyte alkaline phosphatase]]
| align="center" style="background:#F5F5F5;" + |
* WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L
* More than 80% neutrophils,
* Less than 10% circulating neutrophil precursors with blasts
| align="center" style="background:#F5F5F5;" + |
* Poor prognosis
* Absence of the Philadelphia chromosome or a BCR/ABL fusion gene
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|}


==References==
==References==

Revision as of 21:12, 24 January 2019

Chronic neutrophilic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Chronic neutrophilic leukemia from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic neutrophilic leukemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic neutrophilic leukemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic neutrophilic leukemia differential diagnosis

CDC on Chronic neutrophilic leukemia differential diagnosis

Chronic neutrophilic leukemia differential diagnosis in the news

Blogs on Chronic neutrophilic leukemia differential diagnosis

Directions to Hospitals Treating Chronic neutrophilic leukemia

Risk calculators and risk factors for Chronic neutrophilic leukemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Chronic neutrophilic leukemia (CNL) must be differentiated from other diseases that cause neutrophilia, such as, leukemoid reaction, chronic myeloid leukemia (CML), neutrophilic-chronic myelogenous leukemia (CML-N), myeloproliferative neoplasms/ myelodysplastic syndromes (MPN/MDS) disorders, polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Differentiating [Disease name] from other Diseases

CNL must be differentiated from other diseases that cause neutrophilia.

Differentiating Leukemia from other Diseases

Leukemia must be differentiated from various diseases that cause weight loss, night sweats, hepatosplenomegaly, and palpable lymph nodes, such as hairy cell leukemia, prolymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma. Based on the expression of cell surface markers, the table below differentiates different types of leukemia from other diseases that cause similar clinical presentations:[1]

Disease Etiology Clinical Manifestation Laboratory Findings Gold standard diagnosis Associated findings
Demography History Symptoms Signs
Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other
Acute myelogenous leukemia[2][3]
  • Clonal proliferation of malignant myeloid blast cells in the marrow
  • Genetic abnormalities t(8;21), inv(16), and t(15;17)
+ Rare Mild and asymptomatic NA
  • Persistent or frequent infections
  • Fatal within weeks or months if left untreated
Acute lymphoblastic leukemia[4][5]
  • Arrest of lymphoblasts
  • Chromosomal translocations: t(9;22) , t(12;21), t(5;14), t(1;19)
  • The most common form of cancer in children
  • Peak 2-5 years of age
  • Boys > girls
  • History of cancer
  • History of drug exposure
+ + + NA
  • CNS involvement
Chronic myelogenous leukemia[6][7]
  • Median age 50 years old
+ Abdominal fullness
  • Normal
+
Disease Etiology Demography History Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other Gold standard diagnosis Associated findings
Chronic lymphocytic leukemia[8]
  • The most common leukemia in adults in western countries
  • M > F
  • Median age 70 years old
+ + +

The most common abnormal finding

+
Hairy cell leukemia[9][10]
  • Accumulation of small mature B cell lymphoid cells with abundant cytoplasm and "hairy" projections
  • BRAF mutation
  • Uncommon
  • Median age 50 to 55 years old
  • M >> F
  • More common in Caucasians than Blacks
+ Abdominal fullness
  • Normal
± +

Splenomegaly

Large granular lymphocytic leukemia[11][12]
  • Clonal proliferation of cytotoxic T cells
  • Dysregulation of apoptosis through abnormalities in the Fas/Fas ligand pathway
  • Rare
  • Median age 60 years
  • M = F
  • Autoimmune diseases
  • Lymphoproliferative disorders
± +
  • Mostly asymptomatic
  • Modest lymphocytosis
  • Neutropenia
  • Anemia
  • Thrombocytopenia
  • Large lymphocytes with a condensed round or oval nucleus, abundant pale basophilic cytoplasm, and small azurophilic granules
  • Multiple serological abnormalities including rheumatoid factor, antinuclear antibody, antiplatelet antibodies, antineutrophil antibodies, positive direct Coombs test, hyper- or hypogammaglobulinemia, monoclonal gammopathies, and elevated β2-microglobulin
  • Biopsy and flow cytometry + T-cell receptor gene rearrangement studies
  • Recurrent bacterial infection
Chronic neutrophilic leukemia[13]
  • Mature granulocytic proliferation in the blood and marrow
  • Point mutations in the CSF3R gene
  • Very rare
  • M = F
  • Multiple myeloma
+

The most common clinical finding

  • Pruritus
  • Gout
  • Peripheral blood neutrophilia (> 25 x 109/L) with myeloid precursors (promyelocytes, myelocytes, metamyelocytes)
  • Toxic granulation in the neutrophils
  • Nuclear hypersegmentation
  • Increased myeloid:erythroid ratio > 20:1
  • WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L
  • More than 80% neutrophils,
  • Less than 10% circulating neutrophil precursors with blasts
  • Poor prognosis
  • Absence of the Philadelphia chromosome or a BCR/ABL fusion gene
Disease Etiology Demography History Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other Gold standard diagnosis Associated findings

References

  1. Hoffbrand V, Moss P. Essential Haematology. John Wiley & Sons; 2011
  2. Saif A, Kazmi S, Naseem R, Shah H, Butt MO (August 2018). "Acute Myeloid Leukemia: Is That All There Is?". Cureus. 10 (8): e3198. doi:10.7759/cureus.3198. PMID 30410824. Vancouver style error: initials (help)
  3. Estey EH (April 2013). "Acute myeloid leukemia: 2013 update on risk-stratification and management". Am. J. Hematol. 88 (4): 318–27. doi:10.1002/ajh.23404. PMID 23526416.
  4. Sawalha Y, Advani AS (March 2018). "Management of older adults with acute lymphoblastic leukemia: challenges & current approaches". Int J Hematol Oncol. 7 (1): IJH02. doi:10.2217/ijh-2017-0023. PMC 6176956. PMID 30302234.
  5. Portell CA, Advani AS (April 2014). "Novel targeted therapies in acute lymphoblastic leukemia". Leuk. Lymphoma. 55 (4): 737–48. doi:10.3109/10428194.2013.823493. PMID 23841506.
  6. Saußele S, Silver RT (April 2015). "Management of chronic myeloid leukemia in blast crisis". Ann. Hematol. 94 Suppl 2: S159–65. doi:10.1007/s00277-015-2324-0. PMID 25814082.
  7. Eden RE, Coviello JM. PMID 30285354. Missing or empty |title= (help)
  8. Rai KR, Jain P (March 2016). "Chronic lymphocytic leukemia (CLL)-Then and now". Am. J. Hematol. 91 (3): 330–40. doi:10.1002/ajh.24282. PMID 26690614.
  9. Troussard X, Cornet E (December 2017). "Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment". Am. J. Hematol. 92 (12): 1382–1390. doi:10.1002/ajh.24936. PMC 5698705. PMID 29110361.
  10. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (November 2017). "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology". J Natl Compr Canc Netw. 15 (11): 1414–1427. doi:10.6004/jnccn.2017.0165. PMID 29118233.
  11. Matutes E (March 2017). "Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options". Expert Rev Hematol. 10 (3): 251–258. doi:10.1080/17474086.2017.1284585. PMID 28128670.
  12. Oshimi K (2017). "Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias". Intern. Med. 56 (14): 1759–1769. doi:10.2169/internalmedicine.56.8881. PMC 5548667. PMID 28717070.
  13. Elliott MA, Tefferi A (August 2018). "Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management". Am. J. Hematol. 93 (4): 578–587. doi:10.1002/ajh.24983. PMID 29512199.

Template:WH Template:WS